These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 12891291)

  • 21. [AT1 angiotensin receptor inhibition as a new therapeutic possibility].
    Hunyady L; Nagy L
    Orv Hetil; 1997 Oct; 138(41):2583-90. PubMed ID: 9411327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New therapeutic perspectives associated with the introduction of angiotensin II receptor antagonists].
    Peczkowska M; Kabat M; Janaszek-Sitkowska H
    Pol Arch Med Wewn; 1997 Apr; 97(4):379-90. PubMed ID: 9411416
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
    N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Losartan and renal transplantation.
    Horn S; Holzer H; Horina J
    Lancet; 1998 Jan; 351(9096):111. PubMed ID: 9439500
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Losartan potassium, an angiotensin II receptor antagonist].
    Yoshinaga K
    Nihon Rinsho; 2000 Feb; 58 Suppl 2():140-3. PubMed ID: 11028309
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of hypertension and heart failure with AT1 receptor blockade.
    Weinberg EO; Herzig JW
    J Pak Med Assoc; 2001 Feb; 51(2):81-5. PubMed ID: 11321878
    [No Abstract]   [Full Text] [Related]  

  • 28. Losartan controlled blood pressure and reduced left ventricular hypertrophy but did not alter arrhythmias in hypertensive men with preserved systolic function.
    Zakynthinos E; Pierrutsakos Ch; Daniil Z; Papadogiannis D
    Angiology; 2005; 56(4):439-49. PubMed ID: 16079926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Díez J
    Clin Ther; 2006 Jun; 28(6):832-48. PubMed ID: 16860167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study.
    Naritomi H; Fujita T; Ito S; Ogihara T; Shimada K; Shimamoto K; Tanaka H; Yoshiike N
    Hypertens Res; 2008 Feb; 31(2):295-304. PubMed ID: 18360050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
    Winkler G; Jermendy G; Matos L
    Orv Hetil; 2003 Sep; 144(38):1861-7. PubMed ID: 14596024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C; Schernthaner G
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fetal toxic effects and angiotensin-II-receptor antagonists.
    Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
    Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
    [No Abstract]   [Full Text] [Related]  

  • 35. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
    Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic effects of ACE-inhibition (quinapril) and angiotensin-II-type-1 receptor blockade (losartan) on atrial natriuretic peptide in brain nuclei of rats with experimental myocardial infarction.
    Hu K; Bahner U; Gaudron P; Palkovits M; Ring M; Fehle A; Kruse B; Ertl G
    Basic Res Cardiol; 2001; 96(3):258-66. PubMed ID: 11403419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antihypertensive treatment in patients with diabetes mellitus].
    Zukowska-Szczechowska E; Gosek K; Grzeszczak W
    Pol Arch Med Wewn; 2002 Oct; 108(4):1023-30. PubMed ID: 12642948
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacological properties and its significance in clinical practice].
    Nishikibe M; Ikemoto F
    Nihon Rinsho; 1999 May; 57(5):1124-9. PubMed ID: 10361445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Losartan improves recovery of contraction and inhibits transient inward current in a cellular model of cardiac ischemia and reperfusion.
    Louch WE; Ferrier GR; Howlett SE
    J Pharmacol Exp Ther; 2000 Nov; 295(2):697-704. PubMed ID: 11046108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.